- Erratum
- Open access
- Published:
Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
Retrovirology volume 13, Article number: 35 (2016)
Erratum to: Retrovirology (2016) 13:21 DOI 10.1186/s12977-016-0251-3
The original version of this article unfortunately contained a mistake. The “Acknowledgement” section was incorrect and included Dr. Catherine Tamalet. Dr. Catherine Tamalet should not be included in the “Acknowledgement” section for the following reasons:
Dr. Catherine Tamalet requests to be withdrawn from the “Acknowledgements” section in this article, on the following grounds: (a) No permission was asked of her to be acknowledged. (b) She did not read the manuscript before its publication. (c) The method depicted in the “Methods” section to quantify HIV DNA [“Generic HIV assay (Biocentric, Bandol, Provence) with a cut off of 20 copies/million of peripheral blood mononuclear cells (PBMC)”] is not the method employed in her laboratory. Dr. Tamaret routinely employs an “in-House” method with a cut-off of 20 copies. Dr. Thamalet was in the acknowledgement for fruitful discussion and not for her participation to the study.
Dr. Catherine Tamalet has been removed from the original article [1].
Reference
Loret EP, et al. Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology. 2016;13:21. doi:10.1186/s12977-016-0251-3.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1186/s12977-016-0251-3.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Loret, E.P., Darque, A., Jouve, E. et al. Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology 13, 35 (2016). https://doi.org/10.1186/s12977-016-0264-y
Published:
DOI: https://doi.org/10.1186/s12977-016-0264-y